CN117751198A - 测定皮肤老化的方法 - Google Patents
测定皮肤老化的方法 Download PDFInfo
- Publication number
- CN117751198A CN117751198A CN202280054275.6A CN202280054275A CN117751198A CN 117751198 A CN117751198 A CN 117751198A CN 202280054275 A CN202280054275 A CN 202280054275A CN 117751198 A CN117751198 A CN 117751198A
- Authority
- CN
- China
- Prior art keywords
- skin
- gene expression
- expression
- subject
- years
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 230000009759 skin aging Effects 0.000 title description 9
- 230000014509 gene expression Effects 0.000 claims abstract description 86
- 230000032683 aging Effects 0.000 claims abstract description 62
- 230000004663 cell proliferation Effects 0.000 claims abstract description 26
- 101150041972 CDKN2A gene Proteins 0.000 claims abstract description 15
- 108700042657 p16 Genes Proteins 0.000 claims abstract description 15
- 101150113634 CDKN1A gene Proteins 0.000 claims abstract description 14
- 101150022485 Nfkb1 gene Proteins 0.000 claims abstract description 14
- 101150004620 Cebpb gene Proteins 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- 239000013543 active substance Substances 0.000 claims description 24
- 230000002222 downregulating effect Effects 0.000 claims description 16
- 210000002950 fibroblast Anatomy 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 11
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 claims description 10
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 claims description 10
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 claims description 10
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 claims description 10
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims description 10
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 9
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 claims description 8
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 210000001626 skin fibroblast Anatomy 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 238000000386 microscopy Methods 0.000 claims description 2
- 238000007390 skin biopsy Methods 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 125
- 210000004027 cell Anatomy 0.000 description 19
- 210000004209 hair Anatomy 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000037303 wrinkles Effects 0.000 description 14
- -1 CDKN A Proteins 0.000 description 10
- 239000003974 emollient agent Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 210000000282 nail Anatomy 0.000 description 9
- 230000002062 proliferating effect Effects 0.000 description 9
- 238000011222 transcriptome analysis Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000001815 facial effect Effects 0.000 description 7
- 230000003463 hyperproliferative effect Effects 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 210000001061 forehead Anatomy 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229940108325 retinyl palmitate Drugs 0.000 description 4
- 235000019172 retinyl palmitate Nutrition 0.000 description 4
- 239000011769 retinyl palmitate Substances 0.000 description 4
- 238000007665 sagging Methods 0.000 description 4
- 230000009758 senescence Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 238000010199 gene set enrichment analysis Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007388 punch biopsy Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 239000004101 4-Hexylresorcinol Substances 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 235000019360 4-hexylresorcinol Nutrition 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 208000019751 Anorectal disease Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 244000055346 Paulownia Species 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001273 Polyhydroxy acid Polymers 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 1
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 1
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 1
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 1
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 1
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- XRERONKQLIQWGW-UHFFFAOYSA-N but-1-ene;styrene Chemical class CCC=C.C=CC1=CC=CC=C1 XRERONKQLIQWGW-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229940087559 grape seed Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003699 hair surface Effects 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 150000003772 α-tocopherols Chemical class 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 150000003781 β-tocopherols Chemical class 0.000 description 1
- 150000003785 γ-tocopherols Chemical class 0.000 description 1
- 150000003789 δ-tocopherols Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/148—Screening for cosmetic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
本发明提供了通过测量和/或调节选自细胞增殖速率、NFKB1基因表达、CDKN1A基因表达、CDKN2A基因表达、CEBPB基因表达以及它们的组合的特性来诊断和治疗快速老化皮肤,特别是年轻受试者的快速老化皮肤的方法。
Description
技术领域
本发明提供了诊断和治疗快速老化皮肤,特别是年轻受试者的快速老化皮肤的方法,该方法通过测量和/或调节此类皮肤中的细胞增殖速率、NFKB1基因表达、CDKN1A基因表达、CDKN2A基因表达或CEBPB基因表达来进行。还提供了筛选用于快速老化皮肤的活性剂和其他治疗的方法。
背景技术
皮肤老化的特征通常在于皮肤成纤维细胞功能的损伤,该损伤诱导细胞外基质的损失以及差的再生能力,最终导致皱纹和松垂。在若干特征中,已知增殖能力的丧失是与细胞衰老相关联的成纤维细胞老化的关键标志之一。尽管与老年群体相比,可证明年轻群体中的细胞增殖的显著差异,但是在年轻群体中经常观察到更高的变异性,从而提出了年轻群体中更高的供体间变异性的问题。
细胞衰老最初由Hayflick和Moorhead在1961年描述,其引入了细胞老化的理论,其中细胞具有有限的分裂能力。L.Hayflick,PS.Moorhead,Exp Cell Res 25(1961)585-621。这种增殖潜力的丧失导致细胞衰老所特有的细胞周期停滞。其伴随着细胞形态的改变、衰老相关的β-半乳糖苷酶活性增加以及各种细胞因子、趋化因子、生长因子和蛋白酶的释放,也称为衰老相关分泌表型(SASP)。
J Am Acad Dermatol 2018;78:29-39讨论了年龄为20岁至74岁的白种人女性皮肤中基因表达谱的年龄诱导和光诱导的变化。基因表达和个体发育分析揭示,与氧化应激、能量代谢、衰老和表皮屏障相关的途径从20岁到70岁发生了渐进性变化。发现来自看起来更年轻的女性子集的基因表达模式与实际上更年轻的女性的那些基因表达模式相似。具体地讲,虽然作者注意到在暴露于阳光的面部皮肤中增加的CDKN2A基因表达和老化外观,但是他们还指出在整个年龄组的避光臀部皮肤样品中CDKN2A表达保持相对不变。
Cell Res.2015年5月;25(5):574-87.doi:10.1038/cr.2015.36描述了三维人类面部形态作为稳健的老化标记的用途。在这篇论文中,研究人员使用志愿者的3D面部成像来确定老化的面部特征,并且通过将他们的经算法预测的年龄与他们的实足年龄进行比较来确定缓慢老化者特征和快速老化者特征。将结果与志愿者的血清组成进行比较。没有在细胞水平或遗传水平上进行分析,该方法仅基于老化的外部/视觉迹象。仅当出现明显的老化迹象时,面部成像才诊断出快速老化者。
申请人现在已发现,令人惊讶的是,尽管临床上看起来年轻,但年轻皮肤实际上可能正快速老化,含有快速老化细胞。本发明人已经鉴定了信号传递快速老化皮肤细胞的若干生物途径。这些可继而被治疗、改变或调节以减缓快速老化皮肤的速率。这是特别有利的,因为具有快速老化皮肤的年轻受试者可能不能以其他方式确定需要治疗他们皮肤的老化迹象。
发明内容
本发明提供了一种诊断年轻受试者的快速老化皮肤的方法,该方法包括测量年龄为40岁或更小的受试者的皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达。
本发明还提供了一种评价对快速老化皮肤的治疗功效的方法,该方法依次包括:(a)将该治疗施用于年龄为40岁或更小的受试者的皮肤;以及(b)测量该受试者的皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达。
本发明还提供了筛选用于治疗快速老化皮肤的活性剂的方法,该方法包括:(a)将所述活性剂施用于来自年龄为40岁或更小的受试者的皮肤样品;(b)测量该皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达;(c)将所述测量结果与对照进行比较;以及(d)选择与该对照相比提供以下中的至少一种的所述活性剂:减少皮肤成纤维细胞群倍增时间、下调NFKB1基因表达、下调CDKN1A基因表达、下调CDKN2A基因表达和下调CEBPB基因表达。
附图说明
图1是时间(天)对实施例1中所述的供体在第0天、第4天和第10天的平均细胞计数(×10,000)的点图。
图2是汇总了实施例2中高增殖成纤维细胞和低增殖成纤维细胞之间基因表达的差异分析结果的火山图。
具体实施方式
除非另有定义,否则本文使用的所有技术和科学术语均具有与本发明所属领域的普通技术人员通常理解的含义。将本文提及的所有出版物、专利申请、专利以及其它参考文献以引用方式并入本文。
如本文所用,“产品”任选地为成品包装的形式。在一个实施方案中,包装为容纳该组合物的容器,诸如塑料、金属或玻璃管或罐。产品还可含有另外的包装,诸如用于储存此类容器的塑料或硬纸板盒。在一个实施方案中,产品包含本发明的组合物并且含有指导使用者向皮肤或毛发施用组合物的说明书。
如本文所用,“局部施用”意指例如用手或涂敷器(诸如擦拭物、滚筒或喷雾器)直接涂抹在或铺展在外层皮肤、头皮或毛发上。
如本文所用,“美容上可接受的”意指该术语描述的成分适于与组织(例如,皮肤或毛发)接触使用而不会引起不适当的毒性、不相容性、不稳定性、刺激性、变应性应答等。
如本文所用,“活性剂”是对皮肤或毛发具有美容或治疗效果的化合物(合成的或天然的)。
如本文所用,“美容品”是指能保留、恢复、给予、刺激或增强体美外观或似乎能增进美貌或年轻的美化物质或制品,尤其是涉及组织或皮肤的外观时。
如本文所用,“美容上有效量”意指足以处理或预防一种或多种皮肤老化迹象、但充分低以避免严重副作用的量。化合物或组合物的美容上有效量将会随以下因素而变:所治疗的具体病症、最终用户的年龄和身体状况、所治疗/预防的病症的严重程度、治疗的持续时间、其它治疗的性质、所采用的具体化合物或产品/组合物、所采用的具体美容上可接受的载体等等。
如本文所用,“老化迹象”或“皮肤老化迹象”包括存在包括细纹和皱纹在内的纹路、弹性损失、皮肤不均、斑疤、皮肤厚度减小以及胶原、糖胺聚糖、蛋白聚糖、弹性蛋白或糖蛋白(包括纤连蛋白)的异常或减弱合成。在一个实施方案中,老化迹象选自存在纹路、细纹、皱纹、弹性损失以及胶原、糖胺聚糖、蛋白聚糖、弹性蛋白或糖蛋白(包括纤连蛋白)的异常或减弱合成。
如本文所用,“皱纹”包括微细纹、微皱纹或粗皱纹。皱纹的示例包括但不限于眼睛周围的微细纹(例如“鱼尾纹”)、前额和颊皱纹、眉心纹和嘴部周围的笑纹。
如本文所用,“弹性损失”包括皮肤或组织的弹性或结构完整性的损失,包括但不限于松垂、松弛和松散的组织。弹性或组织结构完整性的损失可由多种因素所致,包括但不限于疾病、老化、激素变化、机械创伤、环境损害,或者是向组织施用产品诸如美容品或药物的结果。
如本文所用,“肤色不均”意指与弥漫状或斑驳状色素沉着相关联的皮肤状况,色素沉着可分类为色素沉着过度,诸如发炎后色素沉着过度。
如本文所用,“斑疤”意指与发红或红斑相关联的皮肤状况。
如本文所用,“改善皮肤的紧致度”意指增强皮肤的紧致度或弹性、预防皮肤的紧致度或弹性损失、或者预防或治疗松垂、松弛和松散的皮肤。皮肤的紧致度或弹性可通过使用皮肤弹性测试仪测量。参见J.Serup、G.Jemec与G.Grove编辑的Handbook Of Non-Invasive Methods And The Skin,第66.1章(2006年)。皮肤弹性或紧致度的损失可由多种因素所致,包括但不限于老化、环境损害或向皮肤施用美容品的结果。
如本文所用,“改善皮肤的肌理”意指使皮肤表面平滑以除去皮肤表面上的隆起块或裂隙。
如本文所用,“改善皮肤中皱纹的外观”意指预防、延缓、停止或逆转皮肤上皱纹和微细纹形成的过程。
如本文所用,“预防”是指降低患上给定病症、疾病或障碍的风险。
更广泛地讲,本发明的方法和组合物还可用于治疗或预防美容的、皮肤病学的或其他病症和障碍,包括但不限于与皮肤、指/趾甲和毛发相关的感染、皮肤或黏膜皮肤组织的失衡或紊乱;口腔、阴道和肛门粘膜;角化障碍;炎症;与内在和外在老化相关联的变化,以及可能与皮肤系统相关或可能与皮肤系统无关的其他变化。表现形式包括但不限于油性皮肤;痤疮;红斑痤疮;老年斑;瑕疵皮肤;疹斑;脂肪团;皮肤病;皮炎;皮肤、指/趾甲和毛发感染;头皮屑;皮肤、指/趾甲和毛发的干燥或松弛;干燥症;炎症或湿疹;弹性组织变性;疱疹;角化过度;皮肤色素沉着过度;鱼鳞病;角化病;雀斑;黑斑;斑点皮肤;假性毛囊炎;光老化和光损伤;瘙痒症;牛皮癣;皮纹;妊娠纹;皮肤、指/趾甲板和毛发变薄;疣;皱纹;口腔或齿龈疾病;刺激、发炎、发红、不健康、受损或异常粘膜、皮肤、毛发、指/趾甲、鼻孔、耳道、肛门或阴道病症;真皮组分的分解、缺陷合成或修复;胶原、糖胺聚糖、蛋白聚糖和弹性蛋白的异常或减弱合成,以及此类组分在表皮中的水平降低;不均匀的肤色;皮肤、指/趾甲和毛发表面不均匀和粗糙;皮肤、指/趾甲和毛发的回弹力、弹性和可卷曲性损失或减少;松弛;缺乏皮肤、指/趾甲和毛发润滑和光泽;指/趾甲和毛发脆性和分叉;皮肤泛黄;反应性、刺激或毛细管扩张的皮肤;以及暗沉且看起来较老的皮肤、指/趾甲和毛发。此外,本发明的组合物可用于皮肤、指/趾甲和毛发的一般护理;改善皮肤肌理和毛孔、发亮和红润;使皮肤柔软、光滑、清新、均衡、明显干净、均匀肤色且更加亮白;增加皮肤填充度和丰满度;以及用于皮肤漂白和增亮以及伤口愈合;减少或防止腋下、裆部、手掌或身体的其它部分出汗或有汗液。
如本文所用,术语“受试者”意指人类。受试者可以是“年轻”受试者,即年龄为40岁或更小。受试者的年龄可以为35岁或更小。受试者年龄可以为20-35岁。
如本文所用,“快速老化皮肤″意指表现出与具有较大实足年龄的皮肤类似的一种或多种亚临床老化迹象的皮肤。
如本文所用,“缓慢老化皮肤″意指随着此类皮肤的实足年龄表现出一种或多种亚临床老化组分迹象的皮肤。
如本文所用,“亚临床老化迹象”意指尚未被视觉感知的表型特征,诸如细胞或分子老化迹象。
如本文所用,“对照”意指具有与测试的皮肤样品基本上相同的(即,在小于或大于约5岁内)实足年龄的皮肤的参考值。
除非另外指明,否则百分比或浓度是指重量百分比或重量浓度(即%(重量/重量))。除非另外阐明,否则所有范围均包括端值,例如,“4至9”包括端值4和9。
诊断快速老化皮肤的方法
本发明涉及诊断受试者的快速老化皮肤的方法。
优选地,受试者是年轻受试者。
优选地,皮肤是面部皮肤。例如,皮肤可以来自脸颊、前额、下巴、眼睛区域或颈部,然而,可使用来自身体的任何其他部分的皮肤,例如手臂、手、躯干或腿。
优选地,皮肤样品来自角质层。
该方法包括测量受试者的皮肤样品中的选自细胞增殖速率、NFKB1基因表达、CDKN1A基因表达、CDKN2A基因表达、CEBPB基因表达以及它们的组合的特性。
该方法可包括测量皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达。
该方法可包括测量年龄为40岁或更小的受试者的皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达。
可以以多种方式收集样品,如本领域已知的,包括穿孔活组织检查或非侵入式方法诸如胶带剥离、通过使用仪器诸如SkinSkan测量体内色氨酸荧光或其他类似方法、共焦拉曼或反射共焦显微镜或其他显微镜/光谱法、微针贴片或其他类型的基于粘合剂贴片的皮肤活检装置。
优选地,样品通过非侵入式方法收集。
可分析样品的细胞增殖速率。在此类情况下,可使用本领域已知的方法测量样品的例如以天为单位的皮肤成纤维细胞群体倍增时间。例如,下文实施例1中所述的增殖测定可用于测量细胞增殖速率。
在其中群体倍增时间为至少4天的皮肤可被诊断为快速老化皮肤。
可分析样品的以下基因表达中的一者或多者。转录组分析方法也是本领域所熟知的。例如,可使用下文实施例2中所述的转录组分析方法。
可分析样品的NFKB1基因表达。
与对照相比,在其中NFKB1基因表达上调的皮肤可被诊断为快速老化皮肤。
可分析样品的CDKN1A基因表达。
与对照相比,在其中CDKN1A基因表达上调的皮肤可被诊断为快速老化皮肤。
可分析样品的CDKN2A基因表达。
与对照相比,在其中CDKN2A基因表达上调的皮肤可被诊断为快速老化皮肤。
可分析样品的CEBPB基因表达。
与对照相比,在其中CEPBP表达上调的皮肤可被诊断为快速老化皮肤。
如果上述基因中一者的表达比相同基因在来自年龄在约+/-5岁内的供体的成纤维细胞群体中的平均表达高至少约20%,则认为该基因上调。
如果上述基因中一者的表达比相同基因在来自年龄在约+/-5岁内的供体的成纤维细胞群体中的平均表达高至少约30%,则认为该基因上调。
评价对快速老化皮肤的治疗功效的方法
本发明还提供评价对快速老化皮肤的治疗功效的方法。
可如上所述选择和收集受试者和皮肤。受试者可以为40岁或更小的年龄。
该方法包括首先将待评价的治疗施用于受试者的皮肤。接着,可测量受试者的皮肤样品中的以下特性中的一者:细胞增殖速率、NFKB1基因表达、CDKN1A基因表达、CDKN2A基因表达、CEBPB基因表达以及它们的组合。可测量细胞增殖连同NFKB1基因表达、CDKN1A基因表达、CDKN2A基因表达和CEBPB基因表达中的一者或多者。
任选地,在向受试者的皮肤施用治疗之前,可最初测量相同特性中的一者或多者以提供基准。这些可用作对照。
可如本文所述分析样品的细胞增殖速率。例如,下文实施例1中所述的增殖测定可用于测量细胞增殖速率。
如果治疗为皮肤样品提供少于4天的群体倍增时间,则可认为其对于治疗快速老化皮肤是有效的。
可分析样品的以下基因表达中的一者或多者。转录组分析方法也是本领域所熟知的。例如,可使用下文实施例2中所述的转录组分析方法。
可分析样品的NFKB1基因表达。
如果治疗提供NFKB1基因表达的下调,则可认为其对于治疗快速老化皮肤是有效的。
可分析样品的CDKN1A基因表达。
如果治疗提供CDKN1A基因表达的下调,则可认为其对于治疗快速老化皮肤是有效的。
可分析样品的CDKN2A基因表达。
如果治疗提供CDKN2A基因表达的下调,则可认为其对于治疗快速老化皮肤是有效的。
可分析样品的CEBPB基因表达。
如果治疗提供CEBPB基因表达的下调,则可认为其对于治疗快速老化皮肤是有效的。
如果待分析基因的表达降低至少约20%,则可认为上述治疗中的一者是有效的。
如果待分析基因的表达降低至少约30%,则可认为上述治疗中的一者是有效的。
治疗
治疗包括改善、预防或逆转皮肤病症、疾病或障碍的任何手段。它们可抑制、减缓进展,或延迟此类皮肤病症、疾病或障碍的发作,可以是身体上的(例如稳定可辨别的症状),也可以是生理上的(例如稳定身体参数),或者两者兼有。
该治疗可通过局部施用来施用。
该治疗可以口服施用,即以可摄取的形式。
该治疗可以为局部施用化妆品组合物。
该组合物可含有一种或多种活性剂。该活性剂可以是美容上可接受的活性剂。该活性剂可以为抗老化剂。
该活性剂包括例如抗老化剂、抗痤疮剂、光泽控制剂、抗微生物剂、抗炎剂、抗真菌剂、抗寄生虫剂、外用止痛剂、防晒剂、光防护剂、抗氧化剂、角质层分离剂、表面活性剂、保温剂、营养物质、维生素、增能剂、抗汗剂、收敛剂、除臭剂、紧致剂、抗硬剂以及用于毛发和/或皮肤调理的试剂。
基于该组合物的总重量,该组合物中活性剂的量可在按该组合物的重量计约0.001%至约20%,例如,按该组合物的重量计约0.005%至约10%,诸如按组合物的重量计约0.01%至约5%的范围内。
该活性剂可选自例如α羟基酸,多羟基酸,二肽包括N-酰基二肽衍生物,三肽,过氧化苯甲酰,D-泛醇类胡萝卜素,类视色素诸如视黄醇和棕榈酸视黄酯,神经酰胺,多不饱和脂肪酸,必需脂肪酸,酶诸如漆酶,酶抑制剂,矿物质,激素诸如雌激素,类固醇如氢化可的松、2-二甲基氨乙醇,铜盐诸如氯化铜,多肽诸如六胜肽和三胜肽、含铜的那些,辅酶Q10,氨基酸诸如脯氨酸,维生素,乳糖醛酸,乙酰辅酶A,烟酸,核黄素,硫胺,核糖,电子转运蛋白诸如NADH和FADH2,天然提取物诸如来自芦荟、野甘菊、燕麦片、莳萝、黑莓、毛泡桐、阿斯彭柠檬的那些,间苯二酚诸如4-己基间苯二酚,姜黄素,糖胺诸如N-乙酰基葡糖胺,以及它们的衍生物和混合物。
维生素的示例包括但不限于维生素A、维生素B类(诸如,维生素B3、维生素B5和维生素B12)、维生素C、维生素K和不同形式的维生素E(像α、β、γ和Δ生育酚或它们的混合物)以及它们的衍生物。
其他羟基酸的示例包括但不限于乙醇酸、乳酸、苹果酸、水杨酸、柠檬酸和酒石酸。
抗氧化剂的示例包括但不限于水溶性抗氧化剂,诸如巯基化合物及其衍生物(例如,焦亚硫酸钠和N-酰基-半胱氨酸)、硫辛酸和二氢硫辛酸、白藜芦醇、乳铁蛋白以及抗坏血酸和抗坏血酸衍生物(例如,抗坏血酸棕榈酸酯和抗坏血酸多肽)。适用于本发明的组合物中的油溶性抗氧化剂包括但不限于丁基化羟基甲苯、类视色素(例如,视黄醇和棕榈酸视黄酯)、生育酚类(例如,醋酸生育酚酯)、生育三烯酚类和泛醌。含有适用于本发明的组合物中的抗氧化剂的天然提取物包括但不限于:含有类黄酮和异黄酮类以及它们的衍生物(例如染料木黄酮和木质素异黄酮(diadzein))的提取物、含有白藜芦醇的提取物等等。此类天然提取物的示例包括葡萄籽、绿茶、松树皮和蜂胶。
化妆品组合物还可包含美容上可接受的局部用载体。该载体可占组合物的约25重量%至约99.99重量%(例如占组合物的约80重量%至约99重量%)。在本发明的优选实施方案中,美容上可接受的局部用载体包括水。
可将组合物制成多种产品类型,包括(但不限于)洗剂、霜剂、凝胶、棒状物、喷剂、膏剂、清洁液体洗剂和固体皂、洗发剂和护发剂、发胶、糊剂、泡沫、粉末、摩丝、剃须霜、擦拭物、贴片、水凝胶、成膜产品、面膜和皮肤面膜、膜和化妆品,如粉底和睫毛膏。这些产品类型可含有多种美容上可接受的局部用载体,包括但不限于溶液、悬浮液、乳液(诸如微乳液和纳米乳液)、凝胶、固体和脂质体。下面是此类载体的非限制性示例。其它载体可由本领域的普通技术人员进行配制。
可用于本发明的组合物可被配制为溶液。溶液通常包含水性溶剂或有机溶剂(例如,约50%至约99.99%或约90%至约99%的美容上可接受的水性溶剂或有机溶剂)。合适的有机溶剂的示例包括:丙二醇、聚乙二醇、聚丙二醇、甘油、1,2,4-丁三醇、山梨醇酯、1,2,6-己三醇、乙醇以及它们的混合物。
可用于本主题发明的组合物可配制为包含润肤剂的溶液。此类组合物优选含有约2%至约50%的润肤剂。如本文所用,“润肤剂”是指用于诸如通过预防水经表皮从皮肤流失来预防或缓解干燥的物质。润肤剂的示例包括但不限于在Pepe、Wenninger和McEwen编辑的International Cosmetic Ingredient Dictionary and Handbook,第2930-2936页(美国化妆品及香料协会,Washington,D.C.,第9版,2002)(在下文中,“ICI手册”)中所述的那些。特别合适的润肤剂的示例包括植物油、矿物油、脂肪酸酯等。
可由此类溶液制备洗剂。洗剂通常含有约1%至约20%(例如,约5%至约10%)的润肤剂和约25%至约90%(例如,约60%至约80%)的水。
可由溶液配制的另一类产品为霜膏。霜膏通常包含约5%至约50%(例如,约10%至约20%)的润肤剂和约25%至约85%(例如,约50%至约75%)的水。
本发明的组合物可包含水,或者另选地为无水的或为不包含水而是包含有机溶剂和/或有机硅溶剂、油、脂质和蜡的膏剂。膏剂可含有动物油或植物油或半固体烃类的简单底料。油膏剂可含有约2%至约10%的润肤剂和约0.1%至约2%的增稠剂。增稠剂的示例包括但不限于ICI手册第2979-2984页中所述的那些。
组合物可被配制为乳液。如果局部用载体是乳液,则约1%至约10%(例如约2%至约5%)的该局部用载体含有乳化剂。乳化剂可为非离子的、阴离子的或阳离子的。乳化剂的示例包括但不限于ICI手册第2962-2971页中所述的那些。
洗剂和霜膏可被配制为乳液。通常此类洗剂含有0.5%至约5%的一种或多种乳化剂。此类霜膏通常含有约1%至约20%(例如,约5%至约10%)的润肤剂;约20%至约80%(例如30%至约70%)的水;以及约1%至约10%(例如,约2%至约5%)的乳化剂。
水包油型和油包水型的单乳液皮肤护理制剂诸如洗剂和霜膏是美容领域中熟知的并且可用于本主题发明。多相乳液组合物,诸如水包油包水型或油包水包油型,也可用于本主题发明。一般来讲,此类单乳液或多相乳液含有水、润肤剂和乳化剂作为主要成分。
该组合物也可配制为凝胶(例如,使用合适的胶凝剂的水性凝胶、醇类凝胶、醇/水凝胶或油性凝胶)。用于水性凝胶和/或醇凝胶的合适胶凝剂包括但不限于天然树胶、丙烯酸和丙烯酸酯聚合物和共聚物以及纤维素衍生物(例如羟甲基纤维素和羟丙基纤维素)。适用于油(诸如矿物油)的胶凝剂包括但不限于氢化丁烯/乙烯/苯乙烯共聚物和氢化乙烯/丙烯/苯乙烯共聚物。此类凝胶通常含有约0.1重量%至5重量%的此类胶凝剂。
该组合物也可被配制成固体制剂(例如,蜡基棒、条皂组合物、粉末或含有粉末的擦拭物)。
除了上述组分外,该组合物还可含有多种其它油溶性物质和/或水溶性物质,这些物质通常用于组合物中,按本领域既定的水平用于皮肤和毛发上。
该组合物中还可存在多种其它物质,如本领域已知的。这些包括湿润剂、pH调节剂、螯合剂(如,EDTA)、芳香剂、染料和防腐剂(如,对羟基苯甲酸脂)。
包含此类组合物的组合物和产品可使用本领域熟知的方法来制备。
在一个实施方案中,该组合物具有低pH。例如,pH可以小于约4或小于约3.3。然而,组合物不需要具有低pH。
局部用组合物可包含缓冲剂,诸如乳酸、柠檬酸、苹果酸、酒石酸、葡糖酸、或葡糖酸内酯。优选地,缓冲剂为乳酸。
通常,该组合物包含约3重量%至约12重量%,或约4重量%至约8重量%的缓冲剂。
筛选用于治疗快速老化皮肤的活性剂的方法
本发明提供了筛选用于治疗快速老化皮肤的活性剂的方法,如下所述。
可如上所述选择和收集受试者和皮肤。
待筛选的活性剂包括上述活性剂。例如,待筛选的活性剂可以为抗老化活性剂。
该方法包括:(a)将该活性剂施用于皮肤样品;(b)测量所述皮肤样品中选自细胞增殖速率、NFKB1基因表达、CDKN1A基因表达、CDKN2A基因表达、CEBPB基因表达以及它们的组合的特性;(c)将所述特性与对照进行比较;以及(d)选择与该对照相比提供以下中的至少一种的所述活性剂:减少皮肤成纤维细胞群倍增时间、下调NFKB1基因表达、下调CDKN1A基因表达、下调CDKN2A基因表达和下调CEBPB基因表达。
该方法可包括:(a)将所述活性剂施用于来自年龄为40岁或更小的受试者的皮肤样品;(b)测量该皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达;(c)将所述测量结果与对照进行比较;以及(d)选择与该对照相比提供以下中的至少一种的所述活性剂:减少皮肤成纤维细胞群倍增时间、下调NFKB1基因表达、下调CDKN1A基因表达、下调CDKN2A基因表达和下调CEBPB基因表达。
可如本文所述分析样品的细胞增殖速率。例如,下文实施例1中所述的增殖测定可用于测量细胞增殖速率。
可使用本领域熟知的转录组分析方法来分析样品的基因表达。例如,可使用下文实施例2中所述的转录组分析方法。
实施例1
在以下研究中测试来自年轻供体和年老供体的皮肤细胞的增殖速率。将结果与皮肤科医生对供体的专家临床分级进行比较。
志愿者被分成两组:
组1:年龄范围20-33岁的“年轻供体”(n=9),和
组2:年龄范围61-68岁的“老年供体”(n=9)。
细胞增殖速率分析如下。从在前臂掌侧上采集的两个3mm-穿孔活检组织的生长物中分离出皮肤成纤维细胞,并在37℃下在具有5%CO2的90%加湿培养箱中在补充有10%胎牛血清、1%两性霉素、0.04%庆大霉素和1%Glutamax的Dulbecco改良的Eagle培养基中培养。将细胞扩增并每周传代。
使用以下增殖测定评估来自两组的成纤维细胞的增殖速率。
增殖测定
将细胞以4.10^4个细胞/孔铺板于24孔板中,并在37℃下在具有5%CO2的90%加湿培养箱中在补充有10%胎牛血清、1%两性霉素、0.04%庆大霉素和1%Glutamax的经Dulbecco改良的Eagle培养基中培养4天或10天。在第4天或第10天,分离细胞并用CoulterZ1ST(Beckman Coulter France)细胞计数器计数。
图1示出了年轻供体和年老供体的增殖速率。其是时间(天)对供体在第0天、第4天和第10天的平均细胞计数(×10,000)的点图。数据表明,令人惊讶的是尽管一些年轻供体表现出与其年龄一致的高增殖能力,但其他供体示出与在年老供体中观察到的类似的低增殖能力。
具体地,表1示出了在第4天年轻供体和年老供体中高增殖者和低增殖者中的每一者的平均群体倍增时间(“PD时间”,以天为单位)。细胞增殖在第10天达到稳定水平。(因为细胞应当处于增殖/指数期以计算群体倍增时间,所以从第10天起的增殖数据不包括在计算中。)
表l中:
PD=[ln(收集的细胞数)-ln(接种的细胞数)]/ln(2)
PD时间=[接种和收集之间的天数]/PD。
年轻供体、高增殖者具有2.76天的平均PD时间。年老供体具有4.43天的平均PD时间,年轻供体、低增殖者出乎意料地具有5.44天的平均PD时间,其与年老供体的PD时间没有统计学上的显著差异。表2示出了统计学分析的结果。使用双侧学生t检验进行统计学分析。
表1
表2
***在统计学上显著
NS在统计学上不显著
由皮肤科医生对相同的供体进行17种皮肤老化迹象的专业评级。在年轻供体和年老供体之间,17种迹象中的13种在统计学上显著不同(也使用双侧学生t检验)。然而,在年轻供体(高增殖者)和年轻供体(低增殖者)之间,17种迹象中只有3种显著不同:干燥、前额皱纹数目和前额皱纹深度。
令人惊讶的是,某些年轻供体(其皮肤看起来年轻,几乎没有临床老化迹象)具有一定程度的与来自年老供体的皮肤一致的低增殖皮肤细胞。这指示在年轻皮肤中存在亚临床老化,并且表明此类年轻皮肤相对于实足年龄而言正在快速老化。
实施例2
使用以下转录组分析对来自实施例1的年轻供体的成纤维细胞进行转录组分析。
转录组分析
将来自年轻供体组的细胞在80%-90%汇合时收获、沉淀并冷冻。使用RNeasyPlus Mini Kit(Qiagen,France)用Qiacube根据制造商的说明提取总RNA。对总RNA进行转录组微阵列谱分析。
对于转录组阵列数据,使用在limma R软件包中实现的RMA框架进行背景校正,然后进行分位数归一化(QN)。此程序旨在归一化阵列之间的中值表达。在归一化之前和之后使用大量数据可视化进行质量检查以正确评估QN和过滤的影响。使用limma进行差异分析,以鉴定在高增殖者(即缓慢老化者)和低增殖者(即快速老化者)之间差异表达的基因。然后使用fgsea R软件包进行基因集富集分析(GSEA),以使用分子特征数据库(https://www.gsea-msigdb.org/gsea/msigdb)提示的基因集鉴定在上调或下调的基因中过表达的基因集。
结果在图2中示出,其是汇总了对高增殖成纤维细胞和低增殖成纤维细胞之间的基因表达进行差异分析的结果的火山图。蓝色点描绘了在低增殖成纤维细胞中上调的基因,然而橙色点描绘了在高增殖成纤维细胞中上调的基因(FDR q<0.1和绝对log2 FC>log2(1.2))。以黑色突出的点对应于属于来自Reactome数据库的衰老途径的基因。
与NFKB1、CDKN1A、CDKN2A和CEBPB相关的基因在年轻供体低增殖者的成纤维细胞中被上调。已知这些标记与细胞衰老相关联。
这些结果证实了年轻供体的亚群的存在令人惊讶地表现出与在年老供体中观察到的那些增值能力相似的增殖能力。低增殖的年轻成纤维细胞显示出早期衰老的特征。衰老产生促炎微环境,已知其不仅促成皮肤老化迹象如伤口愈合缺陷、皱纹或松垂的出现,而且促成年龄相关疾病诸如癌症的发展。
该数据示出,年轻人群出乎意料地包括缓慢皮肤老化者和快速皮肤老化者两种。
Claims (11)
1.一种诊断年轻受试者的快速老化皮肤的方法,所述方法包括测量年龄为40岁或更小的受试者的皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达。
2.根据权利要求1所述的方法,所述方法还包括将所述细胞增殖速率或基因表达与对照进行比较。
3.根据权利要求2所述的方法,其中所述细胞增殖速率的对照是至少4天的皮肤成纤维细胞群倍增时间。
4.根据权利要求2所述的方法,其中基因表达的所述对照是比来自年龄在约+/-5岁内的供体的成纤维细胞群体中所述基因的平均表达高至少约20%的表达。
5.根据权利要求1所述的方法,其中所述受试者年龄为20岁至35岁。
6.根据权利要求1所述的方法,其中所述皮肤样品通过非侵入式方法获得,所述非侵入式方法选自胶带剥离、测量体内色氨酸荧光、显微镜/光谱法、微针贴片和基于粘合剂贴片的皮肤活检装置。
7.一种评价对快速老化皮肤的治疗功效的方法,所述方法依次包括:(a)将所述治疗施用于年龄为40岁或更小的受试者的皮肤;以及(b)测量所述受试者的皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达。
8.根据权利要求7所述的方法,所述方法还包括将所述测量结果与对照进行比较。
9.根据权利要求7所述的方法,其中所述治疗是局部施用化妆品组合物。
10.根据权利要求7所述的方法,其中所述受试者年龄为20岁至35岁。
11.一种筛选用于治疗快速老化皮肤的活性剂的方法,所述方法包括:
(a)将所述活性剂施用于来自年龄为40岁或更小的受试者的皮肤样品;
(b)测量所述皮肤样品中的细胞增殖速率和选自NFKB1、CDKN1A、CDKN2A、CEBPB以及它们的组合的基因的表达;(c)将所述测量结果与对照进行比较;以及(d)选择与所述对照相比提供以下中的至少一种的所述活性剂:减少皮肤成纤维细胞群倍增时间、下调NFKB1基因表达、下调CDKN1A基因表达、下调CDKN2A基因表达和下调CEBPB基因表达。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163228959P | 2021-08-03 | 2021-08-03 | |
US63/228,959 | 2021-08-03 | ||
PCT/IB2022/057132 WO2023012645A1 (en) | 2021-08-03 | 2022-08-01 | Method of determining skin aging |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117751198A true CN117751198A (zh) | 2024-03-22 |
Family
ID=82943251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280054275.6A Pending CN117751198A (zh) | 2021-08-03 | 2022-08-01 | 测定皮肤老化的方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230041417A1 (zh) |
CN (1) | CN117751198A (zh) |
AU (1) | AU2022322103A1 (zh) |
BR (1) | BR112024002205A2 (zh) |
CA (1) | CA3228174A1 (zh) |
CO (1) | CO2024001025A2 (zh) |
WO (1) | WO2023012645A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020075179A1 (en) * | 2018-10-11 | 2020-04-16 | Ashok Shukla | A weather proof pressure sensitive adhesive tape composition and a process for production thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4526971B2 (ja) * | 2005-02-14 | 2010-08-18 | 株式会社資生堂 | フィブュリン−5を指標とした皮膚老化状態の評価方法 |
WO2010065567A2 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
PL2588062T3 (pl) * | 2010-06-30 | 2019-11-29 | Avon Prod Inc | Zastosowanie tiliacora triandra w kosmetykach i ich kompozycjach |
WO2012151346A1 (en) * | 2011-05-03 | 2012-11-08 | Dermachip Inc. | Expression signatures of genes and gene networks associated with skin aging |
TW201805005A (zh) * | 2016-08-11 | 2018-02-16 | 台灣利得生物科技股份有限公司 | Antcin M 可藉由活化Nrf2 及SIRT-1 消除皮膚纖維母細胞在高血糖狀態下之加速老化 |
FR3097558B1 (fr) * | 2019-06-24 | 2021-06-25 | Oreal | Méthode de diagnostic d’un vieillissement prématuré de la peau |
-
2022
- 2022-08-01 CA CA3228174A patent/CA3228174A1/en active Pending
- 2022-08-01 US US17/878,371 patent/US20230041417A1/en active Pending
- 2022-08-01 CN CN202280054275.6A patent/CN117751198A/zh active Pending
- 2022-08-01 AU AU2022322103A patent/AU2022322103A1/en active Pending
- 2022-08-01 BR BR112024002205A patent/BR112024002205A2/pt unknown
- 2022-08-01 WO PCT/IB2022/057132 patent/WO2023012645A1/en active Application Filing
-
2024
- 2024-01-30 CO CONC2024/0001025A patent/CO2024001025A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2024001025A2 (es) | 2024-03-07 |
US20230041417A1 (en) | 2023-02-09 |
CA3228174A1 (en) | 2023-02-09 |
AU2022322103A1 (en) | 2024-01-25 |
BR112024002205A2 (pt) | 2024-04-30 |
WO2023012645A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230381075A1 (en) | Botanical and bacterial extracts displaying retinol-like activity | |
EP3372220B1 (en) | Use of gingerone or derivatives thereof for reducing or delaying the signs of skin ageing | |
EP0946138B1 (fr) | Utilisation d'un extrait de potentilla erecta dans le domaine de la cosmetique et de la pharmacie | |
KR101460669B1 (ko) | 점액을 분비하는 어류로부터 수득한 점액을 함유하는 화장료 조성물 | |
JPH09255547A (ja) | 皮膚外用剤 | |
US20230041417A1 (en) | Method of determining skin aging | |
US20240148632A1 (en) | Topical compositions containing n-acyl dipeptide derivatives and glycolic acid | |
EP2120917B1 (en) | Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy | |
CN115025001A (zh) | 一种具有多重美白祛斑功效的胜肽组合物及其应用 | |
EP4381101A1 (en) | Method of determining skin aging | |
CN111166688A (zh) | 青蒿烯作为保湿抗皱、抗衰老成分在化妆品中的应用 | |
US20230301890A1 (en) | Compositions comprising urolithins | |
WO2024028834A1 (en) | Reduction of signs of skin aging | |
WO2023209592A1 (en) | Topical compositions containing vitamin c | |
CN116270275A (zh) | 蔓荆子黄素促进胶原蛋白和/或弹性蛋白生成的应用 | |
CN116327626A (zh) | 猫眼草酚d促进胶原蛋白和/或弹性蛋白生成的应用 | |
Sadick | Futuristic approaches to skin care | |
CN117898978A (zh) | 松露油复配物促进胶原蛋白和/或弹性蛋白生成的应用 | |
KR20170049158A (ko) | 옥타펩타이드를 주성분으로 하는 피부 주름개선용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |